
Liquidity, historical trends, and peer comparisons.
According to Beam Therapeutics Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 13.00. This represents a change of -9.78% compared to the average of 14.41 of the last 4 quarters.
The mean historical Current Ratio of Beam Therapeutics Inc. over the last ten years is 5.22. The current 13.00 Current Ratio has changed 148.93% with respect to the historical average. Over the past ten years (40 quarters), BEAM's Current Ratio was at its highest in in the March 2026 quarter at 16.99. The Current Ratio was at its lowest in in the March 2018 quarter at 0.
Average
5.22
Median
4.89
Minimum
0.31
Maximum
13.09
Discovering the peaks and valleys of Beam Therapeutics Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.77%
Maximum Annual Current Ratio = 13.09
Minimum Annual Increase = -44.01%
Minimum Annual Current Ratio = 0.31
| Year | Current Ratio | Change |
|---|---|---|
| 2025 | 13.09 | 171.35% |
| 2024 | 4.82 | -18.13% |
| 2023 | 5.89 | 20.53% |
| 2022 | 4.89 | -18.05% |
| 2021 | 5.96 | 97.97% |
| 2020 | 3.01 | -7.15% |
| 2019 | 3.24 | -44.01% |
| 2018 | 5.79 | 1.77% |
The current Current Ratio of Beam Therapeutics Inc. (BEAM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
7.93
5-year avg
6.93
10-year avg
5.22
Beam Therapeutics Inc.’s Current Ratio is less than CRISPR Therapeutics AG (16.21), greater than Intellia Therapeutics, Inc. (6.65), greater than Editas Medicine, Inc. (3.19), greater than Precision BioSciences, Inc. (10.47), greater than Cellectis S.A. (1.37), greater than Allogene Therapeutics, Inc. (10.72), greater than Fate Therapeutics, Inc. (4.85), greater than Caribou Biosciences, Inc. (6.49),
| Company | Current Ratio | Market cap |
|---|---|---|
| 16.21 | $5.01B | |
| 6.65 | $1.72B | |
| 3.19 | $417.74M | |
| 10.47 | $224.12M | |
| 1.37 | $117.86M | |
| 10.72 | $411.13M | |
| 4.85 | $243.61M | |
| 6.49 | $47.64M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Beam Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Beam Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Beam Therapeutics Inc.'s Current Ratio?
How is the Current Ratio calculated for Beam Therapeutics Inc. (BEAM)?
What is the highest Current Ratio for Beam Therapeutics Inc. (BEAM)?
What is the 3-year average Current Ratio for Beam Therapeutics Inc. (BEAM)?
What is the 5-year average Current Ratio for Beam Therapeutics Inc. (BEAM)?
How does the current Current Ratio for Beam Therapeutics Inc. (BEAM) compare to its historical average?